

## AMENDMENTS TO THE CLAIMS

The following Listing of Claims replaces all prior versions and listings of claims in this application.

### Listing of Claims:

Claim 1 (currently amended): ~~The use of a~~ A pharmaceutical composition comprising one compound, which is a serotonin reuptake inhibitor, and another compound, which is a H<sub>3</sub> receptor antagonist, inverse agonist or partial agonist ~~for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post-traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors.~~

Claim 2 (currently amended): A pharmaceutical composition comprising a compound that is both ~~The use of a~~ H<sub>3</sub> receptor antagonist, inverse agonist or partial agonist ~~for the preparation of a pharmaceutical composition to be used in combination with~~ and a serotonin reuptake inhibitor.

Claim 3 (currently amended): A method of augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor, comprising administering to a patient in need thereof a therapeutically effective amount of ~~The use of a~~ H<sub>3</sub> receptor antagonist, inverse agonist or partial agonist ~~for the preparation of a pharmaceutical composition useful for~~

~~augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor.~~

Claim 4 (currently amended): The A method of treating depression or an affective disorder, comprising administering a therapeutically effective amount of a H<sub>3</sub> receptor antagonist, inverse agonist or partial agonist to a patient being treated with a serotonin reuptake inhibitor and in need thereof use according to any of claims 2-3 wherein the serotonin reuptake inhibitor is used for the treatment of depression, anxiety disorders and other affective disorders, including generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder or social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to a SRI.

Claim 5 (currently amended): A method of treating depression or an affective disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 1 ~~The use of a compound, which is a serotonin reuptake inhibitor, and a compound, which is a H<sub>3</sub> receptor antagonist, inverse agonist or partial agonist, for the preparation of a pharmaceutical composition for use in the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention~~

~~deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors.~~

Claim 6 (currently amended): The method of claim 5, wherein the compound is use  
~~according to any of claims 1-5 wherein a selective serotonin reuptake inhibitor is used.~~

Claim 7 (currently amended): The method of claim 5, wherein the compound The use  
~~according to any of claims 1-6 wherein a compound, which is selective for the H<sub>3</sub> receptor, is used.~~

Claim 8 (currently amended): The method of claim 5, wherein the compound is use  
~~according to any of claims 1-7 wherein an antagonist or an inverse agonist at the H<sub>3</sub> receptor is used.~~

Claim 9 (currently amended): The method of claim 8, wherein the compound is use  
~~according to any of claim 1-8 wherein a H<sub>3</sub> receptor antagonist is used.~~

Claim 10 (currently amended): The method of claim 6, wherein the serotonin reuptake  
inhibitor use ~~according to any of claims 1-9 wherein the SRI is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, duloxetine, vilazodone, nefazodone, imipramine, femoxetine, and clomipramine.~~

Claim 11 (currently amended): The method of claim 5, use according to any of claims 1-  
10 wherein the H<sub>3</sub> receptor ligand is selected from Thioperamide, Ciproxifan, Iodophenpropit, GR 175737, Iodoproxyfan, Proxifan, Perceptin, JB 98064, VUF 9153, A 304121, ABT923, ABT 834, A 923, A 320436, A 331440, A 349413, A 349821, A 417022, A 423579, A 424835, A 431404, AQ 0145, FUB 181, FUB 360, FUB 407, FUB 637, FUB 836, GR 168320, GSK 189254A, GSK 207040A, GT 2016, GT 2104, GT 2209, GT 2212, GT 2227, GT 2232, GT 2390, GT 2349, GT 2355, GT 2394, Imoproxifan, Impentamine, JNJ 5207852, NNC 0038 0000 1049, NNC 0038 0000 1202, SCH 50971, SCH 79687, UCL 1199, UCL 1283, UCL 1390, UCL

1409, UCL 1860, UCL 1972, UCL 2065, UCL 2138, UCL 2173, UCL 2283, Verongamine, VUF 4163, VUF 5000, and VUF 5182.

Claim 12 (currently amended): A The pharmaceutical composition according to claim 1, further comprising a ~~compound, which that is a serotonin reuptake inhibitor, and another compound, which is a H<sub>3</sub> receptor antagonist, inverse agonist or partial agonist,~~ and optionally pharmaceutically acceptable carrier carriers or diluent diluents.

Claim 13 (currently amended): A The pharmaceutical composition according to claim 1, ~~12~~ wherein the serotonin reuptake inhibitor used is a selective serotonin reuptake inhibitor.

Claim 14 (currently amended): A The pharmaceutical composition according to claim 1, ~~any of claims 12-13~~ wherein the H<sub>3</sub> antagonist, inverse agonist of or partial agonist is selective for the H<sub>3</sub> receptor.

Claim 15 (currently amended): A The pharmaceutical composition according to claim 1 ~~any of claims 12-14~~, wherein the H<sub>3</sub> ligand is a H<sub>3</sub> receptor antagonist.

Claim 16 (currently amended): A The pharmaceutical composition according to claim 1, ~~wherein any of claims 12-15 characterized in that~~ the serotonin uptake inhibitor is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, duloxetine, vilazodone, nefazodone, imipramine, femoxetine and clomipramine.

Claim 17 (currently amended): A pharmaceutical composition according to claim 1, ~~wherein any of claims 12-16 characterized in that~~ the H<sub>3</sub> ligand is selected from Thioperamide, Ciproxifan, Iodophenpropit, GR 175737, Iodoproxyfan, Proxifan, Perceptin, JB 98064, VUF 9153, A 304121, ABT923, ABT 834, A 923, A 320436, A 331440, A 349413, A 349821, A 417022, A 423579, A 424835, A 431404, AQ 0145, FUB 181, FUB 360, FUB 407, FUB 637, FUB 836, GR 168320, GSK 189254A, GSK 207040A, GT 2016, GT 2104, GT 2209, GT 2212, GT 2227, GT 2232, GT 2390, GT 2349, GT 2355, GT 2394, Imoproxifan, Impentamine, JNJ 5207852, NNC 0038 0000 1049, NNC 0038 0000 1202, SCH 50971, SCH 79687, UCL 1199, UCL 1283, UCL 1390, UCL 1409, UCL 1860, UCL 1972, UCL 2065, UCL 2138, UCL 2173, UCL 2283, Verongamine, VUF 4163, VUF 5000, and VUF 5182.

Claim 18 (currently amended): ~~A pharmaceutical composition according to any of claims 12-17, which is adapted for~~ The method of claim 5, wherein the active ingredients are administered by simultaneous administration of the active ingredients.

Claim 19 (currently amended): ~~A pharmaceutical composition according to claim 18 wherein the active ingredients are contained~~ The method of claim 5, wherein the active ingredients are administered in the same unit dosage form.

Claim 20 (currently amended): ~~A pharmaceutical composition according to any of claims 12-17 which is adapted for~~ The method of claim 5, wherein the active ingredients are administered by sequential administration of the active ingredients.

Claim 21 (currently amended): ~~The pharmaceutical composition according to any of claims 18 or 20~~ The method of claim 5, wherein the active ingredients are administered contained in discrete dosage forms.

Claim 22 (currently amended): A method for ~~the identification of~~ identifying compounds useful for the treatment of depression ~~or an affective disorder, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post-traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors,~~ comprising, in any order:

(a) measuring the ability of test compounds to inhibit serotonin reuptake and selecting the compounds that have an IC<sub>50</sub> value below 50 nM;

(b) measuring the affinity of test compounds to the H<sub>3</sub> receptor and selecting the compounds that have an affinity,

and thereafter measuring the efficacy of the selected compounds at the H<sub>3</sub> receptor and selecting the compounds which are antagonists, inverse agonists or partial agonists at the receptor.

Claim 23 (currently amended): A The method according to claim 22 wherein the compound has an affinity in step (b) of less than 50 nM[[:]].

Claim 24 (currently amended): A The method according to claim ~~any of claims 22 and 23~~, wherein the compound has an affinity in step (b) of less than 10 nM[[:]].

Claim 25 (currently amended): A compound ~~identified according to any of the claims 22-24~~ that inhibits serotonin reuptake and has an IC<sub>50</sub> value below 50 nM; and has an affinity to the H<sub>3</sub> receptor.

Claim 26 (new): A method of treating depression or an affective disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 2.

Claim 27 (new): The method of claim 26, wherein the serotonin reuptake inhibitor is a selective serotonin reuptake inhibitor.

Claim 28 (new): The method of claim 26, wherein the H<sub>3</sub> receptor antagonist, inverse agonist or partial agonist is selective for the H<sub>3</sub> receptor.

Claim 29 (new): The method of claim 26, wherein the H<sub>3</sub> receptor antagonist, inverse agonist or partial agonist is an antagonist or an inverse agonist at the H<sub>3</sub> receptor.

Claim 30 (new): The method of claim 29, wherein the H<sub>3</sub> receptor antagonist, inverse agonist or partial agonist is a H<sub>3</sub> receptor antagonist.

Claim 31 (new): The pharmaceutical composition according to claim 2, further comprising a pharmaceutically acceptable carrier or diluent.

Claim 32 (new): The pharmaceutical composition according to claim 2, wherein the H<sub>3</sub> ligand is a H<sub>3</sub> receptor antagonist.

Claim 33 (new): The method of claim 4, wherein the affective disorder is selected from anxiety disorders, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, eating disorders, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to a serotonin reuptake inhibitor.

Claim 34 (new): The method of claim 33, wherein the eating disorder is selected from, bulimia, anorexia, and obesity.

Claim 35 (new): The method of claim 5, wherein the affective disorder is selected from anxiety disorders, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, eating disorders, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to a serotonin reuptake inhibitor.

Claim 36 (new): The method of claim 35, wherein the eating disorder is selected from, bulimia, anorexia, and obesity.

Claim 37 (new): The method of claim 22, wherein the affective disorder is selected from anxiety disorders, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, eating disorders, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to a serotonin reuptake inhibitor.

Claim 38 (new): The method of claim 37, wherein the eating disorder is selected from bulimia, anorexia, and obesity.

Claim 39 (new): The method of claim 26, wherein the affective disorder is selected from anxiety disorders, generalized anxiety disorder, panic anxiety, obsessive compulsive

disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, eating disorders, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to a serotonin reuptake inhibitor.

Claim 40 (new): The method of claim 39, wherein the eating disorder is selected from, bulimia, anorexia, and obesity.

Claim 41 (new): The compound of claim 25, wherein the compound has an affinity to the H<sub>3</sub> receptor of less than 50 nM.

Claim 42 (new): The compound of claim 41, wherein the compound has an affinity to the H<sub>3</sub> receptor of less than 10 nM.